Chinese General Practice ›› 2022, Vol. 25 ›› Issue (09): 1148-1154.DOI: 10.12114/j.issn.1007-9572.2021.02.138
• Review • Previous Articles
Recent Developments in the Prevention and Treatment of Irritable Bowel Syndrome
1.School of Medicine,Wuhan University of Science and Technology,Hubei 435000,China
2.Hubei Province Key Laboratory of Kidney Disease Occurrence and Intervention,Huangshi Central Hospital,Huangshi 435000,China
*Corresponding author:WU Qingming,Professor,Chief physician,Master supervisor; E-mail:wuhe9224@sina.com
Received:
2021-10-15
Revised:
2021-12-26
Published:
2022-03-20
Online:
2022-03-01
通讯作者:
吴清明
基金资助:
CLC Number:
GAO Lian, HUANG Xiaoming, WU Qingming.
Recent Developments in the Prevention and Treatment of Irritable Bowel Syndrome [J]. Chinese General Practice, 2022, 25(09): 1148-1154.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.138
[1] | 胡玥,吕宾. 肠易激综合征的治疗进展[J]. 中国实用内科杂志,2020,40(2):105-110. DOI:10.19538/j.nk2020020105. |
[2] | FORD A C,SPERBER A D,CORSETTI M,et al. Irritable bowel syndrome[J]. Lancet,2020,396(10263):1675-1688. DOI:10.1016/S0140-6736(20)31548-8. |
[3] | WILEY J W,CHANG L. Functional bowel disorders[J]. Gastroenterology,2018,155(1):1-4. DOI:10.1053/j.gastro.2018.02.014. |
[4] | 李彦楠,杨丽旋,赵钟辉,等. 《2020年中国肠易激综合征专家共识意见》解读[J]. 中国临床医生杂志,2021,49(10):1151-1155. |
[5] | OSTERTAG D,BUHNER S,MICHEL K,et al. Reduced responses of submucous neurons from irritable bowel syndrome patients to a cocktail containing histamine,serotonin,TNFα,and tryptase (IBS-cocktail)[J]. Front Neurosci,2015,9:465. DOI:10.3389/fnins.2015.00465. |
[6] | TÖRNBLOM H,DROSSMAN D A. Psychopharmacologic therapies for irritable bowel syndrome[J]. Gastroenterol Clin N Am,2021,50(3):655-669. DOI:10.1016/j.gtc.2021.04.005. |
[7] | 詹胜刚,王立生. 应激和肠道菌群在肠易激综合征内脏疼痛中的机制研究[J]. 中国微生态学杂志,2017,29(1):122-125. DOI:10.13381/j.cnki.cjm.201701030. |
[8] | EOM S,LEE J,BAEK Y B,et al. Identification and molecular study on the interaction of Schisandrin C with human 5-HT3A receptor[J]. Eur J Pharmacol,2021,906:174220. DOI:10.1016/j.ejphar.2021.174220. |
[9] | SCIAVILLA P,STRATI F,DI PAOLA M,et al. Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients[J]. Appl Microbiol Biotechnol,2021,105(8):3277-3288. DOI:10.1007/s00253-021-11264-4. |
[10] | TRAINI C,IDRIZAJ E,GARELLA R,et al. Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model[J]. J Cell Mol Med,2021,25(14):6988-7000. DOI:10.1111/jcmm.16710. |
[11] | 周长丽. 罗马Ⅳ标准下肠易激综合征相关风险因素及运动干预的实证研究[D]. 长春:吉林大学,2019. |
[12] | NG Q X,SOH A Y S,LOKE W,et al. The role of inflammation in irritable bowel syndrome (IBS)[J]. J Inflamm Res,2018,11:345-349. DOI:10.2147/jir.s174982. |
[13] | CARUSO C,COLANTUONO S,CELI G,et al. Modulation of gut microbiota in patients with IBS and systemic nickel allergy after diet and probiotic supplementation:a pilot study[J]. J Biol Regul Homeost Agents,2020,34(5):1929-1934. DOI:10.23812/20-162-l. |
[14] | WANG B,ZHAO W,ZHAO C S,et al. What impact do Rome IV criteria have on patients with IBS in China?[J]. Scand J Gastroenterol,2019,54(12):1433-1440. DOI:10.1080/00365521.2019.1698650. |
[15] | AZIZ I,TÖRNBLOM H,PALSSON O S,et al. How the change in IBS criteria from RomeⅢ to RomeⅣ impacts on clinical characteristics and key pathophysiological factors[J]. Am J Gastroenterol,2018,113(7):1017-1025. DOI:10.1038/s41395-018-0074-z. |
[16] | VASANT D H,PAINE P A,BLACK C J,et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome[J]. Gut,2021,70(7):1214-1240. DOI:10.1136/gutjnl-2021-324598. |
[17] | WILLIAMS J,MILLS M T,WARRINER D R. Implications of the 2021 National Institute for Health and Care Excellence atrial fibrillation guidelines[J]. Br J Hosp Med (Lond),2021,82(9):1-4. DOI:10.12968/hmed.2021.0419. |
[18] | ORLANDO A,TUTINO V,NOTARNICOLA M,et al. Improved symptom profiles and minimal inflammation in IBS-D patients undergoing a long-term low-FODMAP diet:a lipidomic perspective[J]. Nutrients,2020,12(6):1652. DOI:10.3390/nu12061652. |
[19] | PICARELLI A,GRECO N,SCIUTTINI F,et al. High consumption of Nickel-containing foods and IBS-like disorders:late events in a gluten-free diet[J]. Ecotoxicol Environ Saf,2021,222:112492. DOI:10.1016/j.ecoenv.2021.112492. |
[20] | ALTOMARE A,DI ROSA C,IMPERIA E,et al. Diarrhea predominant-irritable bowel syndrome (IBS-D):effects of different nutritional patterns on intestinal dysbiosis and symptoms[J]. Nutrients,2021,13(5):1506. DOI:10.3390/nu13051506. |
[21] | 赵爱华. 心理护理干预在肠易激综合征治疗中的应用[J]. 世界最新医学信息文摘,2017,17(2):288,292. DOI:10.19613/j.cnki.1671-3141.2017.102.162. |
[22] | LINDFORS P,UNGE P,ARVIDSSON P,et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized,controlled trials[J]. Am J Gastroenterol,2012,107(2):276-285. DOI:10.1038/ajg.2011.340. |
[23] | 徐桂兴,黄碧清,熊俊. 针灸治疗肠易激综合征的系统评价[J]. 中华中医药学刊,2016,34(9):2171-2174. DOI:10.13193/j.issn.1673-7717.2016.09.035. |
[24] | PEI L,CHEN H,GUO J,et al. Effect of acupuncture and its influence on visceral hypersensitivity in IBS-D patients:Study protocol for a randomized controlled trial[J]. Medicine:Baltimore,2018,97(21):e10877. DOI:10.1097/md.0000000000010877. |
[25] | ZHENG H,JIN S,SHEN Y L,et al. Chinese herbal medicine for irritable bowel syndrome:a meta-analysis and trial sequential analysis of randomized controlled trials[J]. Front Pharmacol,2021,12:694741. DOI:10.3389/fphar.2021.694741. |
[26] | CARRASCO-LABRA A,LYTVYN L,FALCK-YTTER Y,et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)[J]. Gastroenterology,2019,157(3):859-880. DOI:10.1053/j.gastro.2019.06.014. |
[27] | 韩伟,赵丽,周金池,等. 利福昔明在胃肠道疾病中的应用现状[J]. 胃肠病学和肝病学杂志,2020,29(4):466-468,473. |
[28] | HOU Q K,ZHU S L,ZHANG C R,et al. Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice[J]. Biomedecine Pharmacother,2019,118:109206. DOI:10.1016/j.biopha.2019.109206. |
[29] | 赖步洪,吴荣伟,黄金水. 奥替溴铵联合洛哌丁胺治疗改善腹泻型肠易激综合征患者症状及生活质量效果分析[J]. 内科,2017,12(6):798-800. DOI:10.16121/j.cnki.cn45-1347/r.2017.06.23. |
[30] | LI X,LI B,ZHANG J,et al. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome:a systematic review and meta-analysis[J]. Medicine:Baltimore,2021,100(4):e24361. DOI:10.1097/md.0000000000024361. |
[31] | LEMBO A J,COVINGTON P S,DOVE L S,et al. Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D:Additional post hoc analyses of Phase 3 trials[J]. Neurogastroenterol Motil,2020,32(4):e13774. DOI:10.1111/nmo.13774. |
[32] | LACY B E,HARRIS L A,CHANG L,et al. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D:a subgroup analysis of phaseⅢtrials[J]. Therap Adv Gastroenterol,2019,12:1756284819841290. DOI:10.1177/1756284819841290. |
[33] | CARRASCO-LABRA A,LYTVYN L,FALCK-YTTER Y,et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)[J]. Gastroenterology,2019,157(3):859-880. DOI:10.1053/j.gastro.2019.06.014. |
[34] | 林懋惺,杨丽. 5-HT受体与肠易激综合征[J].医学综述,2007,13(5):398-400. |
[35] | CHEN Y,CHU F,LIN J,et al. The mechanisms of action of WeiChang'An Pill (WCAP) treat diarrhoea-predominant irritable bowel syndrome (IBS-D) using network pharmacology approach and in vivo studies[J]. J Ethnopharmacol,2021,275:114119. DOI:10.1016/j.jep.2021.114119. |
[36] | TAYLOR D C A,ABEL J L,MARTIN C,et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data:the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR)[J]. J Med Econ,2020,23(10):1072-1083. DOI:10.1080/13696998.2020.1799816. |
[37] | VU V,FARKAS C,RIYAD O,et al. Enhancement of the enzymatic hydrolysis efficiency of wheat bran using the Bacillus strains and their consortium[J]. Bioresour Technol,2022,343:126092. DOI:10.1016/j.biortech.2021.126092. |
[38] | 李保亚. 马来酸曲美布汀胶囊联合聚乙二醇4000散口服治疗便秘型肠易激综合征的临床疗效[J]. 中国肛肠病杂志,2019,39(5):36-37. |
[39] | 雷云霞,蔡淦. 5羟色胺在肠易激综合征中的作用[J]. 中国中西医结合消化杂志,2005,13(6):410-413. |
[40] | CAMILLERI M,BOECKXSTAENS G. Dietary and pharmacological treatment of abdominal pain in IBS[J]. Gut,2017,66(5):966-974. DOI:10.1136/gutjnl-2016-313425. |
[41] | 曾之晅,汪欢,杨新,鞥.肠易激综合征治疗研究进展[J].中华内科杂志,2017,56(2):140-143. DOI:CNKI:SUN:ZHNK.0.2017-02-022. |
[42] | 邹多武.利那洛肽:慢性便秘和便秘型肠易激综合征的新选择[J].中华消化杂志,2019,39(4):286-288. DOI:10.3760/cma.j.issn.0254-1432.2019.04.016.42. |
[43] | ZHAO Q F,YONG F Y,YAN C,et al. Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation:a meta-analysis[J]. Z Gastroenterol,2021,7(26):2-8. DOI:10.1055/a-1491-1784 |
[44] | HENSTRÖM M,HADIZADEH F,BEYDER A,et al. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M[J]. Gut,2017,66(9):1725-1727. DOI:10.1136/gutjnl-2016-313346. |
[45] | 李媛. 腹泻型、便秘型以及混合型肠易激综合征患者肠道菌群的差异性比较[J]. 世界最新医学信息文摘,2018,18(46):61-62. DOI:10.19613/j.cnki.1671-3141.2018.46.034. |
[46] | FASSOV J,LUNDBY L,LAURBERG S,et al. Three-year follow-up of sacral nerve stimulation for patients with diarrhoea-predominant and mixed irritable bowel syndrome[J]. Colorectal Dis,2017,19(2):188-193. DOI:10.1111/codi.13428. |
[47] | BLACK C J,YUAN Y H,SELINGER C P,et al. Efficacy of soluble fibre,antispasmodic drugs,and gut-brain neuromodulators in irritable bowel syndrome:a systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol,2020,5(2):117-131. DOI:10.1016/S2468-1253(19)30324-3. |
[48] | 王彬,赵威,晋弘,等. 薄荷油治疗肠易激综合征的基础和临床研究进展[J]. 胃肠病学,2017,22(2):118-120. |
[49] | HUSSAIN Z,JUNG D H,LEE Y J,et al. The effect of trimebutine on the overlap syndrome model of Guinea pigs[J]. J Neurogastroenterol Motil,2018,24(4):669-675. DOI:10.5056/jnm18049. |
[50] | GETACHEW B,AUBEE J I,SCHOTTENFELD R S,et al. Ketamine interactions with gut-microbiota in rats:relevance to its antidepressant and anti-inflammatory properties[J]. BMC Microbiol,2018,18(1):222. DOI:10.1186/s12866-018-1373-7. |
[51] | GUNN D,GARSED K,LAM C,et al. Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron[J]. Aliment Pharmacol Ther,2019,50(5):538-546. DOI:10.1111/apt.15420. |
[52] | ZAH V,IMRO M,TATOVIC S,et al. Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment——a retrospective claims analysis[J]. J Opioid Manag,2020,16(6):461-479. DOI:10.5055/jom.2020.0604. |
[53] | RAY K. Yeast probiotics for the treatment of IBD[J]. Nat Rev Gastroenterol Hepatol,2021,18(9):594. DOI:10.1038/s41575-021-00497-3. |
[54] | 尹泉,肖文,赵超,等. 益生菌治疗腹泻型肠易激综合征患者的疗效及对肠道菌群的影响[J]. 深圳中西医结合杂志,2021,31(11):154-156. DOI:10.16458/j.cnki.1007-0893.2021.11.071. |
[55] | WEN Y,LI J,LONG Q,et al. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome:a systematic review and meta-analysis based on seventeen randomized controlled trials[J]. Int J Surg,2020,79:111-119. DOI:10.1016/j.ijsu.2020.04.063. |
[56] | EL-SALHY M,KRISTOFFERSEN A B,VALEUR J,et al. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome[J]. Neurogastroenterol Motil,2021:e14200. DOI:10.1111/nmo.14200. |
[57] | EL-SALHY M,HAUSKEN T,HATLEBAKK J G. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS)[J]. Nutrients,2019,11(6):E1415. DOI:10.3390/nu11061415. |
[58] | TABONE M,BRESSA C,GARCÍA-MERINO J A,et al. The effect of acute moderate-intensity exercise on the serum and fecal metabolomes and the gut microbiota of cross-country endurance Athletes[J]. Sci Rep,2021,11(1):3558. DOI:10.1038/s41598-021-82947-1. |
[59] | HUNT M,MIGUEZ S,DUKAS B,et al. Efficacy of zemedy,a mobile digital therapeutic for the self-management of irritable bowel syndrome:crossover randomized controlled trial[J]. JMIR Mhealth Uhealth,2021,9(5):e26152. DOI:10.2196/26152. |
[1] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[2] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[3] | SU Kaiqi, LYU Zhuan, WU Mingli, LUO Meng, GAO Jing, NIE Chenchen, LIU Hao, FENG Xiaodong. Effect of Electroacupuncture on BDNF/TrkB/PI3K/Akt Pathway and Hippocampal Neuronal Protection in Rats with Learning and Memory Impairment after Ischemia Reperfusion [J]. Chinese General Practice, 2023, 26(33): 4187-4193. |
[4] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[5] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[6] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[7] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[8] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[9] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[10] | WANG Qianqian, WANG Xiaohang, ZHOU Xiaoying, QIU Shanhu, SUN Zilin. Exercise is the Foundation of Weight Loss [J]. Chinese General Practice, 2023, 26(28): 3471-3476. |
[11] | CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470. |
[12] | SUN Xiaolei, LEI Xiaolong, LIN Jiasheng, LI Keliang, GUO Ao, ZHANG Xiaohui. Effect of High Intensity Laser Combined with Physiotherapy Scoliosis Specific Exercise Therapy on Ultrasound Morphology of Multifidus Muscles in Idiopathic Scoliosis Patients with Low Back Pain [J]. Chinese General Practice, 2023, 26(27): 3456-3462. |
[13] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
[14] | CHEN Xiaofen, CHEN Yuhan, MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(27): 3349-3354. |
[15] | PEI Bei, CHENG Lin, XU Lingyun. Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients [J]. Chinese General Practice, 2023, 26(27): 3435-3440. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||